Showing results (101-110 of 272) with videos related to

Sort By:
Pageof 28
Urology Case Reports|June 3, 2024
Inflammatory myofibroblastic tumor in a patient with X-Linked hypophosphatemia: A case of Occam's razor or Hickam's dictum?Farhan Chowdry, Kelsey M Miller, Ersan Altun, et al.
Cancer|September 7, 2002
Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinomaJonathan S Goldberg, Manuel Vargas, Alyssa S Rosmarin, et al.
Cell Reports. Medicine|May 18, 2022
A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade responseWilliam H Weir, Peter J Mucha, William Y Kim
Expert Review of Anticancer Therapy|February 19, 2008
mTOR pathway in renal cell carcinomaSara C Hanna, Samuel A Heathcote, William Y Kim
American Journal of Cancer Research|October 6, 2017
Analysis of bladder cancer tumor CpG methylation and gene expression within The Cancer Genome Atlas identifies GRIA1 as a prognostic biomarker for basal-like bladder cancerSloane K Tilley, William Y Kim, Rebecca C Fry
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2021
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder CancerTracy L Rose, Michael R Harrison, Allison M Deal, et al.
Nature Communications|May 24, 2024
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancerWolfgang Beckabir, Mi Zhou, Jin Seok Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II study of sunitinib in patients with metastatic urothelial cancerDavid J Gallagher, Matthew I Milowsky, Scott R Gerst, et al.
American Journal of Clinical Oncology|October 1, 2010
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981Scott T Tagawa, Matthew I Milowsky, Stephanie Jeske, et al.
Journal of the National Cancer Institute|February 16, 2013
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapyAndrea B Apolo, Irina Ostrovnaya, Susan Halabi, et al.
Pageof 28